Akers Biosciences Share Discussion Threads

[norbus] 27/10/2016 10:52

They sowed lots and lots of seeds @ cost of ~ $100m
No Seedling that germinated ever did more than a few leaves then withered and died
Had there been a real demand for all or any, it would have found AKERS and fruit made
They are now talking entry into new venues; Best way forward is to buy small turnover businesses and grow critical mass. More likely , like West Ham's bubbles they will fade and .... Good luck All

[mcmather] 27/10/2016 00:10

A bit of bedtime reading:

We may offer and sell up to $7 million in the aggregate of the securities identified above from time to time in one or more offerings.

The Company plans to target other attractive markets such as aid organizations with purchasing power for rapid infectious disease tests and other biotechnology companies or pharmaceutical manufacturers that may require companion tests to promote patient compliance with a medication regimen or facilitate initial screenings to qualify patients for a particular therapy.

METRON / KetoChek / OxiChek. The Company is currently assessing distribution opportunities with companies specializing in weight loss and/or mass distribution through health-related multilevel marketing organizations.

Akers is continuing its clinical development of the Breath Ketone “Check” disposable breath tube.

Akers’ recently patented Rapid Blood Cell Separation Technology, marketed under the brand name seraSTAT®.....Akers may consider partnerships with other medical device companies, functioning as an Original Equipment Manufacturer, as the benefits of the seraSTAT® Rapid Blood Cell Separation Technology can be integrated into other assay platforms.

We do not have a strong presence in many emerging markets (speak to Walt about those, ahem, previous 'orders'...) but are seeking to enter into agreements to enable us to enter other international markets in the current fiscal year.

We currently employ 36 full-time equivalent employees, contractors or consultants, which include 9 in research and development, 6 in general and administrative, 10 in sales and marketing and 11 in direct and indirect manufacturing.

We intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement.

Holders of Series A Preferred Stock shall be entitled to receive preferential dividends at a rate of $0.00135 per share of Series A Preferred Stock per annum (for struggling to make big losses). Such dividends shall compound annually and be fully cumulative, and shall accumulate from the date of original issuance of the Series A Preferred Stock.

The Series A Preferred Stock is convertible at any time into common stock, at the rate of 0.0320512 shares of common stock for each 1 share of Series A Preferred Stock, for an additional payment of $0.05 per each 1 share of converted Series A Preferred Stock, subject to adjustment (the “Conversion Price”).

[norbus] 26/10/2016 13:09

Never mind glasses; $7m more! Robbin Aker Hood will be in the money again.

[mcmather] 25/10/2016 09:15

Crikey - need new glasses! It is $811.30(3); page 3 of the filing.

[norbus] 25/10/2016 09:10

what do you mean reg fee? is that underwriting? $960000/7000000 1/4 13.5% ??

[mcmather] 25/10/2016 09:07

Looking to raise $7m. Registration fee will be £811k... (edit, minus about $810k...)

[norbus] 20/10/2016 10:46

Sounds Odd; hype, blackmail or mix of both.

[mcmather] 19/10/2016 22:35

14 Oct 2016 - 5 Stocks With Superb Earnings Revisions — SNOW AKER RPT BBRY LILAK.

Akers Biosciences, Inc.. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AKER stock.

[mcmather] 19/10/2016 22:31

The stock of Akers Biosciences Incorporated (NASDAQ:AKER) registered a decrease of 54.71% in short interest. AKER’s total short interest was 10,100 shares in October as published by FINRA. Its down 54.71% from 22,300 shares, reported previously.

[rivaldo] 11/10/2016 14:58

The weakening pound is certainly nicely increasing the value of US shares held by UK shareholders!

At the current $3.28 the US is now trading at around 265p in sterling terms.

[mcmather] 07/10/2016 00:12

1 Oct 2016 - Manufacturing Batch Technician, Akers Biosciences - Thorofare, NJ 08086
The advert doesn't provide any real insight re why hiring:

[rivaldo] 30/8/2016 15:07

Trading in the USA at $3.70, i.e around 280p in UK terms.

FYI here's a full transcript of the Q2 conference call with the CEO and FD:

[algernon2] 27/8/2016 22:24

"Akers Biosciences' OxiChek device monitors a person's wellbeing.."

New Video from Raymundo:

[algernon2] 22/8/2016 19:28

"Groovy" as I used to say in the sixties.

[rivaldo] 22/8/2016 14:46

Nice start in the USA this afternoon - up to $3.68, i.e around 283p in UK terms.

[rivaldo] 22/8/2016 13:51

Great to see two pieces of good news in the last week whilst I've been on hols.

The Chubeworks settlement is particularly good news since the entire $1.25m had already been written off, whereas now AKR will receive a very useful $500k of cash plus $750k of stock for resale.

[algernon2] 20/8/2016 17:19

More news:

"Akers Biosciences settles dispute with ChubeWorkx.."

"The company is pleased with the outcome of the settlement agreement which ends a long running dispute and allows Akers Bio to regain the full worldwide rights to its BreathScan technology, unencumbered by any licensing claims."
Akers Biosciences Inc (NASDAQ:AKER, LON:AKR) has come to a settlement with a former distributor that will see it recoup U$1.25mln in the form of product and cash.

It follows a long-running legal wrangle with a firm called ChubeWorkx, which had a licensing agreement Akers.

The latter was seeking to recover what was owed from a promissory note and will now do so by taking delivery of US$750,000-worth of BreathScan alcohol detectors, which it will resell. It will also get US$500,000 in cash.

Additionally, the settlement frees Akers to sell its breakthrough breath tests worldwide after regaining certain rights from ChubeWorkx.

In return ChubeWorkx will receive a 5% gross revenue royalty on Akers’ breath technology up to US$5mln.

Akers chief executive John Gormally said: "The company is pleased with the outcome of the settlement agreement which ends a long running dispute and allows Akers Bio to regain the full worldwide rights to its BreathScan technology, unencumbered by any licensing claims.

“We believe this technology - particularly as it is applied within our new range of breath tests for the health and wellness industry - is very valuable to Akers Bio and as such we believe the terms of the settlement agreement are beneficial for our shareholders." "

Thanks to ProactiveInvestors for the info:

[algernon2] 19/8/2016 00:26

"Akers Biosciences Completes Study on First Rapid Breath Test for Oxidative Stress"

18/08/2016

[norbus] 12/8/2016 08:14

There are always Gazillion tests for every walk of illness addiction ; Just seems that few want to use AKR kits ; Walt should of been in the condom business more in demand than PIFA tests

you will not have long to find out if China takes up the $2m balance

[wigwammer] 11/8/2016 16:39

"We remain bullish this is going to happen (announcement of large network adoption) sooner than later, sorry I can't give a definitive date. But those will all be consummated as mentioned before the end of this year". Feel free to listen again.Did someone in the call state there are 4 million+ chlamydia tests undertaken pa?

[mcmather] 11/8/2016 16:18

Norbus, if you didn't listen, it's worthwhile listening to Walt on about the financing and June 2016 being the first cash positive month. A strange fella. Though Gormally does appear to offer some hope.

[norbus] 11/8/2016 15:45

mcm

They persuade newbie buyers to take a punt on a big stuffing, schedule installments and a rebate for stock take-back. I am still of the opinion that they must buy businesses that have sale-able products that can grow . Their items seem to be lightweight novelties; Maybe they should develop viagra for the Nigerian market